Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines : a report from the Groupe Français d'immunothérapie

• Published in: World journal of urology 2005-07, Vol.23 (3), p.161-165
• Main Authors: NEGRIER, Sylvie, GOMEZ, Frédéric, DOUILLARD, Jean-Yves, RAVAUD, Alain, CHEVREAU, Christine, BUCLON, Murielle, PEROL, David, LASSET, Christine, ESCUDIER, Bernard
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Clinical Trials, Phase II as Topic; Databases, Factual - statistics & numerical data; Female; Humans; Interferons - therapeutic use; Interleukin-2 - therapeutic use; Kidney Neoplasms - drug therapy; Kidney Neoplasms - secondary; Kidneys; Life Sciences; Male; Medical sciences; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Nephrology. Urinary tract diseases; Other; Predictive Value of Tests; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Failure; Tumors of the urinary system
• ISSN: 0724-4983; 1433-8726
• DOI: 10.1007/s00345-004-0467-z

Interleukin-2 (IL2) or/and interferon (IFN) are routinely used for treating patients with metastatic renal cell cancer. However, results are disappointing since most patients experience treatment failure. Within 6 years, the Groupe Français d'Immunothérapie enrolled 782 patients in successive multicenter trials using cytokine regimens. Univariate and multivariate analyses were performed on this large prospective database to identify prognostic factors for treatment response or failure. We identified two independent factors predictive of response to cytokine treatment: having only one metastatic organ site and receiving a combination of cytokine treatments. We also identified four independent factors predictive of rapid progression under treatment: presence of hepatic metastases, short interval from renal tumor to metastases (